2021
DOI: 10.1016/j.esmoop.2021.100238
|View full text |Cite
|
Sign up to set email alerts
|

Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey

Abstract: Background Germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-related pancreatic ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents. This study aimed at exploring safety profile, dose intensity, and activity of different chemotherapy regimens in this setting. Patients and methods gBRCA1-2pv PDAC patients of any age and clinical tumor stage who completed a first course of chemotherapy were eligible. A descriptive analysis of chemotherapy… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(6 citation statements)
references
References 45 publications
1
5
0
Order By: Relevance
“…This encouraged us to take advantage of a profound response and consider a personalized surgical approach with potential curative intent both on primary and metastatic lesions. Second, germline BRCA1/2 mutations have been associated, even though not univocally, with enhanced toxicity to platinum compounds [19][20][21]. This case is consistent with some of these previous reports, since we observed the occurrence of a G4 neutropenia despite granulocyte stimulating factor (G-CSF) support given as secondary prophylaxis.…”
Section: Discussionsupporting
confidence: 91%
“…This encouraged us to take advantage of a profound response and consider a personalized surgical approach with potential curative intent both on primary and metastatic lesions. Second, germline BRCA1/2 mutations have been associated, even though not univocally, with enhanced toxicity to platinum compounds [19][20][21]. This case is consistent with some of these previous reports, since we observed the occurrence of a G4 neutropenia despite granulocyte stimulating factor (G-CSF) support given as secondary prophylaxis.…”
Section: Discussionsupporting
confidence: 91%
“…The antitumoral treatment was not mentioned in 28 studies; those studies referred to chemotherapy, without specifying which chemotherapy. From those who specifically mentioned any antitumoral treatment, the most frequent antitumoral treatments mentioned were carboplatin [ 14 , 20 , 21 ], oxaliplatin [ 13 , 22 , 23 , 24 , 25 ], bevacizumab [ 23 , 24 ], vinca alkaloids [ 14 , 26 , 27 ], and lenalidomide, thalidomide, and bortezomib [ 11 , 22 , 28 , 29 ].…”
Section: Resultsmentioning
confidence: 99%
“…As far as the severity of constipation is concerned, previous studies explain that the burden related to constipation is more severe as death approaches [ 65 ]. In this systematic review, the severity of constipation is only mentioned in 13 of the 54 studies [ 1 , 11 , 14 , 25 , 29 , 30 , 34 , 35 , 36 , 47 , 48 , 68 , 69 ].…”
Section: Discussionmentioning
confidence: 99%
“…Germline variants in cancer susceptibility genes, in particular BRCA1/2, are clinically relevant targets in metastatic pancreatic ductal adenocarcinoma (PDAC), both for the first-line and maintenance therapy. The patients harboring BRCA1/2 mutations are more responsive to platinum-based chemotherapy agents and poly (ADP-ribose) polymerase (PARP) inhibitors, 1,2 adding a new therapeutic chance for this small subset of PDAC population. Generally, sensitivity to platinum-based chemotherapy is expected to predict the sensitivity to PARP inhibitors, although platinum chemotherapy elicits cell death through both homologous recombination (HR) dependent and non-HR-dependent mechanisms, thus reducing predictive power.…”
Section: Introductionmentioning
confidence: 99%